Literature DB >> 34392477

Estrogen Deficiency Aggravates Fluoride-Induced Liver Damage and Lipid Metabolism Disorder in Rats.

Ya-Ming Yu1, Bian-Hua Zhou2, Yi-Lin Yang1, Cheng-Xiang Guo1, Jing Zhao1, Hong-Wei Wang1.   

Abstract

Estrogen exerts essential role in liver metabolism, and its deficiency is frequently accompanied by a series of metabolic disorder diseases. To investigate the role of estrogen deficiency in fluorine ions (F-) induced liver injury, the ovariectomy (OVX) rat models were performed by surgically removing the ovaries, and the rats from OVX and non-OVX models were exposed to differential dose of F- (0, 25, 50 and 100 mg/L) in drinking water for 90 days. The liver morphological structure was evaluated by hematoxylin-eosin staining. Proliferation ability of hepatocytes was evaluated by 5-bromo-2-deoxyuridine (BrdU) assay. And distribution of lipid droplets in liver tissue was observed via oil red O staining. In addition, the liver function and lipid metabolism parameters in serum were detected by commercial kits. Results showed that F- induced hepatocytes morphological damage and inhibited the proliferation ability of hepatocytes; estrogen deficiency exacerbated these changes. The deposition of lipid droplets in the liver tissue was multiplicative with increased F- dose, especially after estrogen deficiency. In addition, F- exposure increased (P < 0.05 or P < 0.01) serum aminotransferase (ALT), aminotransferase (AST), alkaline phosphatase (ALP), and γ-glutamyl transpeptidase (γ-GT) activities and total bilirubin (T-bil) level; meanwhile, serum triglyceride (TG) and cholesterol (TC) levels were also elevated (P < 0.05 or P < 0.01). F--induced liver function and lipid metabolism indexes were further increased (P < 0.05 or P < 0.01) in the state of estrogen deficiency. In conclusion, estrogen deficiency aggravated F--induced liver damage and lipid metabolism disorder.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cholesterol; Estrogen; Fluoride; Liver function; Ovary; Triglyceride

Mesh:

Substances:

Year:  2021        PMID: 34392477     DOI: 10.1007/s12011-021-02857-1

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  44 in total

Review 1.  The role of lipid droplets in metabolic disease in rodents and humans.

Authors:  Andrew S Greenberg; Rosalind A Coleman; Fredric B Kraemer; James L McManaman; Martin S Obin; Vishwajeet Puri; Qing-Wu Yan; Hideaki Miyoshi; Douglas G Mashek
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

Review 2.  Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Authors:  Pegah Golabi; Logan Rhea; Linda Henry; Zobair M Younossi
Journal:  Hepatol Int       Date:  2019-11-07       Impact factor: 6.047

Review 3.  The Treatment of Disorders of Lipid Metabolism.

Authors:  Klaus G Parhofer
Journal:  Dtsch Arztebl Int       Date:  2016-04-15       Impact factor: 5.594

Review 4.  Treatment of lipid disorders in obesity.

Authors:  Serena Tonstad; Jean-Pierre Després
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-08

Review 5.  Nonalcoholic fatty liver disease: from steatosis to cirrhosis.

Authors:  Geoffrey C Farrell; Claire Z Larter
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 6.  Hepatic glucose and lipid metabolism.

Authors:  John G Jones
Journal:  Diabetologia       Date:  2016-04-05       Impact factor: 10.122

Review 7.  The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes.

Authors:  Dean G Karalis
Journal:  Clin Cardiol       Date:  2008-06       Impact factor: 2.882

8.  Acute exercise does not decrease liver fat in men with overweight or NAFLD.

Authors:  L Bilet; B Brouwers; P A van Ewijk; M K C Hesselink; M E Kooi; P Schrauwen; V B Schrauwen-Hinderling
Journal:  Sci Rep       Date:  2015-04-13       Impact factor: 4.379

9.  Long Noncoding RNA lnc-HC Regulates PPARγ-Mediated Hepatic Lipid Metabolism through miR-130b-3p.

Authors:  Xi Lan; Litao Wu; Nan Wu; Qian Chen; Yue Li; Xiaojuan Du; Chenxi Wei; Lina Feng; Yazhao Li; Ezra Kombo Osoro; Mengyao Sun; Qilan Ning; Xiaofei Yan; Xudong Yang; Dongmin Li; Shemin Lu
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-25       Impact factor: 8.886

10.  Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration.

Authors:  Zheng Sun; Russell A Miller; Rajesh T Patel; Jie Chen; Ravindra Dhir; Hong Wang; Dongyan Zhang; Mark J Graham; Terry G Unterman; Gerald I Shulman; Carole Sztalryd; Michael J Bennett; Rexford S Ahima; Morris J Birnbaum; Mitchell A Lazar
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.